Oscillometry in the COPD Exacerbator Phenotype With Triple Inhaled Therapy Study

Inclusion Criteria: 1. Age over 18 years. 2. Diagnosis of COPD. 3. Severe-moderate COPD measured by FEV1 and stable. 4. Patient receiving dual bronchodilation therapy (LABA/LAMA) for at least the last 4 months prior to study inclusion and meeting clinical criteria to begin triple inhaled therapy. 5. COPD exacerbations (COPD exacerbations). 6. Blood eosinophils \>100 cells/mL in prior laboratory tests. 7. Patient agrees to participate in the study and signs the informed consent form. Exclusion Criteria: 1. COPD in the last 4 weeks, with use of antibiotics or systemic corticosteroids. 2. Chronic lung disease other than COPD. 3. Severe heart failure, with frequent decompensation (in cases of mild decompensation or onset without severe heart disease, do not include the patient within 3 months of decompensation). 4. Active neoplastic processes. 5. Severe renal failure. 5\. ALT greater than 2.5 times the upper limit of normal. 6. Poorly controlled insulin-dependent diabetes or involvement of 1 or more organs. 7\. Positive COVID-19 test (do not include until 3 months after diagnosis by ART or COVID-19 PCR). 8\. Previous treatment with ICS in the last 4 months.